Integrated medical sensors are a company that aims to provide a simple and effective solution for accurate and painless glucose monitoring for diabetes management.
We don’t know a vast amount about them, other than they are a multidisciplinary team, consisting of Caltech graduates with domain expertise in microelectronics, nanotechnology and electrochemical sensors, industry leader in implantable glucose sensor technology, leading endocrinologists, serial entrepreneur business leader with experience in multinational corporations, and industry experts in embedded systems and mechanical design.
The team seems fairly small, and highly centred around Caltech.
What’s their product?
According to their website, the product is:
The world’s first fully-integrated, extremely miniature (less than half of a sesame seed) wireless electrochemical glucose sensor with 10x longer projected lifetime at 10x lower projected cost compared to the available solutions.
The revolutionary IMS sensor is implanted few millimeter under the skin to measure glucose from the interstitial fluid using an integrated electrochemical sensor and relays the real-time data wirelessly to the patient and a secure database (accessible by caregivers, doctors) via a wearable wireless transmitter and a smart reader.
According to the pictures, it’s supposedly half the size of a sesame seed and very cheap, although how cheap remains to be seen.
I think the key thing I’d take away is that it seems to be very like Eversense and requires that it is worn subcutaneously, but much smaller. It also, obviously, requires a reader of some type, but states that this is very small. Given the market penetration of Eversense, I wonder whether this is the best approach?
Will it come to market?
That’s a very good question. So far they have completed pre-clinical trials, but are a very small team, and it’s not clear how well funded they are.
Their model (shown above) also only highlights “Human Testing” rather than anything associated with FDA approval, so I suspect that this is a very long way from anything commercial, if it ever gets there.
Still, it’s good to see nascent companies taking different approaches to diabetes tech!